Regulatory approval

Published by the Health Service Executive. Approved

Maintenance therapy for the treatment of relapsed/refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy.

This is written in the approval document.

Reimbursement

Hospital

Citation

riTUXimab (S/C 1400mg) Maintenance Therapy-84 day, 2025, version number 2a, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6401/599_v2a_riTUXimab_SC_1400mg_Therapy_every_three_months.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	CD20 +	Non-Hodgkin Lymphoma	Rituximab
HSE (1)	CD20 +	Follicular Lymphoma	Rituximab

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2021-03-09	Health Service Executive	Indication approved for reimbursement.